Clinical Trial Update: Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study assessing the impact of severe renal impairment and dialysis on evolocumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia
• Mixed Dyslipidemia

Drugs mentioned

• Evolocumab (evolocumab)

Snippet

Sponsor: Amgen | Conditions: Hyperlipidemia, Mixed Dyslipidemia | Phase 1 | Status: COMPLETED | Results posted: 2016-01-29